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SUMMARY. Entecavir (ETV) is a first-line antiviral therapy
for treating chronic hepatitis B (CHB); however, some
patients have suboptimal response to ETV. Currently, there
are limited data on how to approach these patients. There-
fore, our aim was to compare the effectiveness of two alter-
nate therapies – tenofovir (TDF) monotherapy and
combination therapy of ETV+TDF – in CHB patients with
ETV partial virological response. We conducted a retrospec-
tive study of 68 patients who had partial virological
response to ETV, defined as having detectable HBV DNA
following at least 12 months of ETV, and were switched to
TDF monotherapy (n = 25) or ETV+TDF (n = 43). Patients
were seen in seven US liver/community-based clinics and
started on ETV between 2005 and 2009. The majority of
patients were male; the vast majority were Asian and had
positive hepatitis B e antigen (HBeAg). Patients in both
groups had similar pretreatment characteristics. Complete
viral suppression (CVS) rates with TDF monotherapy and
ETV+TDF were similar after 6 months (71% vs 83%,
P = 0.23) and 12 months (86% vs 84%, P = 0.85), and
there was no statistically significant difference in CVS rates
even when only patients with higher HBV DNA levels at
switch (>1000 IU/mL) were evaluated. Multivariate analy-
sis indicated that ETV+TDF was not an independent predic-
tor of CVS compared to TDF monotherapy (OR = 1.19,
P = 0.63). In conclusion, TDF monotherapy and ETV+TDF
are comparable in achieving CVS in CHB patients with par-
tial virological response to ETV. Long-term alternate ther-
apy with one pill (TDF monotherapy) vs two pills
(ETV+TDF) could lead to lower nonadherence rates and
better treatment outcomes.
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INTRODUCTION
According to the WHO, chronic hepatitis B (CHB) affects
more than 240 million people worldwide, and hepatitis B
virus (HBV) infections lead to an estimated 600 000
deaths per year due to complications such as cirrhosis,
hepatic decompensation and hepatocellular carcinoma
[1–3]. Higher levels of viremia are associated with more
rapid disease progression [4,5]; therefore, the primary goal
of anti-HBV therapy is to achieve complete viral suppres-
sion (CVS) in order to prevent progression and ultimately
premature death [6].
Currently, entecavir (ETV) and tenofovir (TDF) are the
most effective anti-CHB agents based on their efficacy, tol-
erability and minimal rates of antiviral resistance [7,8].
Long-term studies show that ETV can successfully suppress
HBV replication to undetectable HBV DNA levels in over
90% of hepatitis B e antigen (HBeAg)-negative patients
[8,9]. However, in HBeAg-positive individuals with high
levels of viremia, a significant portion of patients experi-
ence only partial virological response [3]. Studies of ETV
monotherapy in HBeAg-positive patients have found that
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approximately 30% of patients were partial virological
responders (detectable HBV DNA levels), 5% were nonre-
sponders (HBV DNA levels ≥105 copies/mL), and 2%
experienced a virological breakthrough after 48 weeks of
ETV [10,11]. Treatment that fails to suppress viral replica-
tion can not only lead to progression of CHB but also to
selection of antiviral resistance mutations [12].
Currently, data are limited regarding how to approach
patients with partial virological responses to ETV. A recent
study by Chen et al. [13] showed that the majority of
patients with HBV DNA >2000 copies/mL after 48 weeks
of ETV did not achieve CVS with additional ETV. Ha et al.
[14] examined patients who remained viremic after at least
24 weeks of ETV at 0.5 mg and observed that increasing
to 1.0 mg did not help the majority achieve CVS. On the
other hand, a study by Pan et al. [15] of patients with par-
tial virological response to ETV suggested that switching to
TDF monotherapy could be an effective option. Another
study by Petersen et al. [16] analysing patients who were
partial virological responders reported that a combination
of ETV+TDF was a safe and efficient treatment. One other
study by Yip et al. [17] evaluating patients with positive
viremia after at least 12 months of ETV concluded that
patients did better when switched to TDF monotherapy or
ETV+TDF compared to combination therapy of ETV and
adefovir (ADV). However, the sample size was small in all
of the above studies and thus limited their conclusions.
Therefore, our goal was to assess the rates of CVS in a lar-
ger, multicentre cohort of CHB patients with partial viro-
logical response to ETV between two alternate therapies:
TDF monotherapy and ETV+TDF combination therapy.
MATERIALS AND METHODS
Study design and population
We conducted a retrospective cohort study of 68 adult
patients with CHB who were seen in liver clinics at Stan-
ford University Medical Center, New York University (NYU)
Langone Medical Center, Ronald Reagan University of Cali-
fornia, Los Angeles (UCLA) Medical Center and four Cali-
fornia community-based clinics in the San Francisco Bay
Area. The study protocol was approved by the Institution
Review Boards at Stanford, NYU, and UCLA. Eligible
patients were CHB patients who had partial virological
response to ETV, defined as having detectable HBV DNA
levels (>60 IU/mL) at the time of treatment modification
following at least 12 months of ETV monotherapy, and
were switched by their providing physician to either TDF
monotherapy or combination therapy of ETV and TDF.
Patients were identified through an electronic query
using the ICD-9 diagnosis code for CHB or by manual
review of clinic patient logs and verified through chart
review or case-based abstraction. Patients who
demonstrated treatment nonadherence or developed viral
resistance to ETV were excluded. ETV resistance was ruled
out in 61 patients by negative genotypic mutation analysis
and in seven patients by the absence of a virological break-
through (increase >1 log10 IU/mL from nadir) while on
ETV. In addition, patients who had human immunodefi-
ciency virus/hepatitis C virus co-infections, were on immu-
nosuppressive therapy, had a history of solid organ
transplant, or had systemic chemotherapy were excluded.
Statistical analysis
Categorical variables were reported as proportions (%), and
continuous variables as mean (SD) or median (range). Cat-
egorical variables were evaluated using the chi-square test,
while continuous variables were evaluated using the Stu-
dent’s t-test if a normal distribution was observed. If a nor-
mal distribution was not observed, then nonparametric
methods were used for evaluation. The Kaplan–Meier
method was used to estimate cumulative rates of CVS, and
comparative analysis was performed using the log-rank test.
Multivariate logistic regression was used to estimate odds
ratios relating various baseline characteristics to the out-
come of CVS rates between the two alternate therapy
groups. Statistical significance was defined as a two-tailed
P-value of 0.05 or less. All statistical analysis was performed
using Stata 11.2 (StataCorp, College Station, TX, USA).
RESULTS
Patient characteristics
Of the two alternate therapy groups, 25 patients were
switched to TDF monotherapy and 43 patients were
switched to ETV+TDF combination therapy. Patients in the
two groups were similar with respect to median age (40 vs
40, P = 0.42) and the proportion of male patients (64% vs
63%, P = 0.92). Of note, the vast majority of patients in
both groups were positive for HBeAg (88% vs 95%,
P = 0.26). Almost all were also Asian (96%). In terms of
prior treatment, more patients in the TDF group received
other antiviral therapy prior to ETV, but the distribution
was not statistically significant (44% vs 23%, P = 0.07).
More patients in the TDF group were also exposed to lami-
vudine (LAM), but again the distribution was not statisti-
cally significant (24% vs 12%, P = 0.18). Based on
genotypic mutation analysis, a total of four patients in the
TDF group and one in the ETV+TDF group had known
LAM resistance.
Both alternate treatment groups were on ETV monother-
apy for a significant duration of time (median of
21 months for TDF vs 25 months for combination) before
being switched to the new regimens. Both TDF monothera-
py and ETV+TDF groups had similar HBV DNA levels prior
to any treatment (7.74 log10 IU/mL vs 7.97 log10 IU/mL
P = 0.43) (Table 1); however, HBV DNA levels at the start
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of ETV monotherapy and at the start of alternate therapy
were slightly lower in the TDF group vs the ETV+TDF
group (6.69 log10 IU/mL vs 7.71 log10 IU/mL, P = 0.01
and 3.10 log10 IU/mL vs 3.57 log10 IU/mL, P = 0.05,
respectively). With regard to alanine aminotransferase
(ALT) levels, both groups had similar median ALT levels
prior to ETV monotherapy (47 vs 51 U/L, P = 0.33) and
at the start of alternate therapy (29 vs 26 U/L, P = 0.41).
Lastly, both treatment groups were followed on alternate
therapies for a significant length of time (median of
16 months and 17 months).
When patients were stratified based on length of ETV
monotherapy prior to TDF or ETV+TDF therapies (≤2 years
vs >2 years), the only characteristic in which there was a
statistically significant difference was HBV DNA levels at
the time of switch to an alternate therapy (3.61 log10 IU/
mL vs 3.15 log10 IU/mL, P = 0.04) (Table 2).
Treatment outcomes
Cumulative rates of CVS in the two patient groups, TDF
monotherapy and ETV+TDF combination therapy, are
depicted in the Kaplan–Meier curves in Fig. 1. Log-rank
analysis demonstrated no statistically significant difference
between the two therapy groups. There was also no statis-
tically significant difference in the rates of CVS of the two
treatment groups in patients with HBV DNA levels
>1000 IU/mL at the time of switch (Fig. 2).
CVS rates after 6 months and 12 months of alternate
therapy were also stratified by duration of prior ETV mono-
therapy: ≤2 years and >2 years before switching to TDF or
ETV+TDF therapy (Fig. 3). For patients on ETV for up to
2 years, CVS rates at 6 and 12 months were similar
between the two therapies (71% vs 70%, P = 0.93 and
77% vs 76%, P = 0.98, respectively). For patients on ETV
monotherapy for longer than 2 years, CVS rates were
lower for the TDF group after 6 months (70% vs 95%,
P = 0.04), but after 12 months, TDF monotherapy patients
had higher CVS rates than the ETV+TDF combination ther-
apy group (100% vs 90%, P = 0.35).
When the CVS rates of TDF monotherapy and ETV+TDF
combination therapy were compared without stratifying
based on length of ETV monotherapy, there was no statisti-
cally significant difference in CVS rates over time (Fig. 4).
After 6 months of new therapy, CVS rates were 71% for
patients on TDF and 83% for patients on ETV+TDF
(P = 0.23). After 12 months, CVS rates were nearly identi-
cal: 86% with TDF and 84% with ETV+TDF (P = 0.85).
Multivariate analysis inclusive of age, time on ETV, and
HBV DNA levels (i) prior to any treatment, (ii) prior to ETV
monotherapy and (iii) at switch to alternate therapy dem-
onstrated that combination therapy of ETV+TDF was not
an independent predictor of CVS compared to TDF mono-
therapy (OR = 1.19, P = 0.63).
DISCUSSION
While ETV is one of the most effective antiviral drugs for
treating CHB [7,8], a small proportion of patients will have
a partial virological response to ETV, especially those posi-
tive for HBeAg and high pretreatment HBV DNA levels.
For these patients, it is unclear whether switching to TDF
would suffice or an add-on approach with TDF is needed.
In this current study, a cohort of 68 patients, who were
mostly Asian (96%) and HBeAg positive (93%), with par-
tial virological response to ETV after a median treatment
duration of 24 months was switched to two alternate ther-
apies: TDF monotherapy and combination therapy of
ETV+TDF. CVS rates with TDF monotherapy and ETV+TDF
were similar at both the 6-month (71% vs 83%) and the
Table 1 Patient characteristics stratified by alternate therapy group [tenofovir (TDF) monotherapy or entecavir (ETV)+TDF
combination therapy] in patients with a partial virological response to ETV
TDF monotherapy (n = 25) ETV and TDF (n = 43) P-value
Median age (years) 40 (19–75) 40 (26–69) 0.42
Male 64% 63% 0.92
HBeAg positive 88% 95% 0.26
Na€ıve HBV DNA (log10 IU/mL) 7.74  1.17 7.97  0.90 0.43
Median time on ETV before switch (months) 21 (12–59) 25 (14–47) 0.71
Median time on alternate therapy (months) 16 (6–56) 17 (6–72) 0.53
Pre-ETV monotherapy
HBV DNA (log10 IU/mL) 6.69  2.03 7.71  1.15 0.01
Median ALT (IU/L) 47 (8–153) 51 (17–156) 0.33
At switch
HBV DNA (log10 IU/mL) 3.10  0.95 3.57  0.90 0.05
Median ALT (IU/L) 29 (12–61) 26 (9–75) 0.41
TDF, tenofovir; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase.
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12-month (86% vs 84%) time points. In addition, there
was no statistically significant difference in CVS rates
between the two alternate therapies even when only
patients with higher HBV DNA levels at the time of switch
(>1000 IU/mL) were evaluated.
Current management guidelines by the European Associ-
ation for the Study of the Liver (EASL) recommend that
treatment adaptation be considered in patients with partial
virological response to ETV at week 48, especially for those
with nondeclining HBV DNA levels [18]. The median time
on ETV in the current study was 21 months for the TDF
group and 25 months for the ETV+TDF group, consistent
with, and exceeding the EASL guidelines. One may argue
that ETV monotherapy can be continued in this patient
population, a treatment option assessed by Zoutendijk et al.
[19]. In this study of European patients, the majority of
ETV partial virological responders with low HBV viremia
(<1000 IU/mL) after 48 weeks of ETV achieved CVS after
24 additional weeks of ETV. However, for those ETV partial
virological responders with HBV DNA levels >1000 IU/mL
after 48 weeks of ETV monotherapy, <10% achieved CVS
after 48 additional weeks of ETV (totalling 2 years of ETV).
In the current study, the majority of patients were treated
with ETV monotherapy for a longer duration before being
switched to an alternate therapy, and at the time of switch
to an alternate therapy, the majority of these patients also
had HBV DNA levels >1000 IU/mL.
A more recently published study by Chen et al. [13]
analysed the effect of prolonged ETV monotherapy on
Table 2 Patient characteristics stratified by duration of entecavir (ETV) monotherapy before switch to an alternate therapy
[tenofovir (TDF) monotherapy or ETV+TDF combination therapy] in patients with a partial virological response to ETV
ETV treatment ≤2 years (n = 36) ETV treatment >2 years (n = 32) P-value
Median age (years) 40 (19–68) 40 (20–75) 0.21
Male 69% 56% 0.26
HBeAg positive 92% 94% 0.74
Prior treatment 28% 34% 0.56
Na€ıve HBV DNA (log10 IU/mL) 7.78  1.12 8.00  0.86 0.43
Pre-ETV monotherapy
HBV DNA (log10 IU/mL) 7.35  1.28 7.31  1.91 0.91
Median ALT (IU/L) 49 (8–156) 51 (19–99) 0.91
At switch
HBV DNA (log10 IU/mL) 3.61  1.04 3.15  0.76 0.04
Median ALT (IU/L) 28 (12–75) 26 (9–63) 0.89
ETV, entecavir; TDF, tenofovir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase.
Fig. 1 Kaplan–Meier analysis of cumulative complete viral
suppression (CVS) rates comparing tenofovir (TDF)
monotherapy and entecavir (ETV) + TDF combination
therapy as alternate therapies in patients with a partial
virological response to ETV.
Fig. 2 Kaplan–Meier analysis of complete viral suppression
(CVS) rates comparing tenofovir (TDF) monotherapy and
entecavir (ETV) + TDF combination therapy as alternate
therapies in patients with a partial virological response to
ETV and HBV DNA levels >1000 IU/mL at the time of
switch.
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CHB patients with a partial virological response after
48 weeks of ETV. Among the subset of 369 patients who
were treatment-na€ıve before ETV, 34 patients failed to
achieve CVS after 48 weeks of ETV and were stratified
based on HBV DNA levels greater or <2000 copies/mL at
48 weeks. With continued ETV, 78% of patients with
<2000 copies/mL achieved CVS with a median follow-up
of 36 months (range 20 to 61 months), while only 27%
of patients with >2000 copies/mL achieved CVS with a
median follow-up of 32 months (range 24 to
48 months). From these results, the authors concluded
that prolonged ETV treatment for treatment-na€ıve
patients with HBV DNA levels >2000 copies/mL after
48 weeks of ETV leads to a poor response and suggested
that an alternate therapy, such as switching to TDF, be
considered.
One other study assessing whether ETV monotherapy
can be continued in patients who demonstrate partial viro-
logical responses to ETV was performed by Yang et al.
[20]. In this study of 1254 Asian patients, while the
majority achieved CVS, a significant minority (approxi-
mately 14%) did not achieve CVS despite a median
follow-up of 30 months (range 6–72 months). Among
HBeAg-positive patients of this same study, the proportion
of patients who did not achieve CVS over the duration of
the study was higher at 20.6%, further suggesting that
some ETV-treated CHB patients may indeed require alter-
nate therapies.
When considering alternate therapies, TDF monothera-
py and combination therapy of ETV+TDF appeared com-
parable in terms of short-term effectiveness based on the
results of the current study. However, TDF monotherapy
may be the better long-term option due to potential
issues of cost and nonadherence. Nonadherence, which
prior studies have identified as one of the major causes
of treatment failure [21,22], is of particular concern for
CHB, as antiviral treatment of this disease involves long-
term commitment. In fact, for drugs with low viral resis-
tance risk such as ETV and TDF, treatment failure may
be attributed more commonly to nonadherence than to
antiviral resistance. Therefore, a new alternate therapy
with one pill (TDF monotherapy) vs two pills (ETV+TDF)
could potentially lead to lower nonadherence rates and
thus better overall treatment outcomes. While this study
only measured outcomes after 6 and 12 months of
alternate therapy, given the long-term treatment of
CHB, potential benefits of TDF monotherapy over
ETV+TDF combination therapy may be seen with longer
follow-up.
Limitations to our study include its retrospective, non-
randomized design and a mostly Asian patient demo-
graphic.
In summary, for CHB patients who demonstrate partial
virological responses to ETV, there was no statistically sig-
nificant difference in CVS rates between TDF monotherapy
and ETV+TDF combination therapy as a new alternate
therapy. Given the economic advantage and the potentially
higher adherence with monotherapy vs combination ther-
apy, TDF monotherapy should be considered for ETV par-
tial virological responders who desire alternate therapy.
Although the current study is multicentre and larger than
prior studies of ETV partial virological responders, the sam-
ple size of the study is still limited. Larger studies are
needed to further evaluate the best long-term management
strategy for this patient population.
Fig. 3 Complete viral suppression (CVS) rates at 6 months
and 12 months in patients with a partial virological
response to entecavir (ETV) on alternate therapy of
tenofovir (TDF) monotherapy or ETV+TDF combination
therapy stratified by duration of ETV monotherapy:
≤2 years vs >2 years.
Fig. 4 Cumulative complete viral suppression (CVS) rates
at 6 months and 12 months in patients with a partial
virological response to entecavir (ETV) on alternate
therapy of tenofovir (TDF) monotherapy or ETV+TDF
combination therapy.
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